Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise ...

Fintel reports that on November 4, 2024, JMP Securities initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise notably Monday, on the happy news that an analyst has initiated coverage ...

In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $14.71 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Biopharma stocks are rarely suitable for short-term investing, so hold onto them. Summit Therapeutics may have a powerful new ...

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.

Spur Therapeutics today announced that Michael Parini, Chief Executive Officer of Spur Therapeutics, and Henning Stennicke, Chief Scientific Officer of Spur Therapeutics, will participate in a panel ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical ...

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on C4 Therapeutics (CCCC – Research Report) today and set a price target ...